About 300 reports

  • filgrastim
  • Neupogen| filgrastim - clinical trials (Year-wise)

“Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations” is a comprehensive report on Neupogen and Neulasta, two market leading drugs (by 2015 sales) used in the treatment of chemotherapy-induced febrile neutropenia. These drugs, both belonging to biotech giant Amgen, fall under...

  • Drug Discovery And Development
  • United States
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Neupogen group

In 2015, Sandoz received FDA approval for Zarxio, a biosimilar version of filgrastim for all the same indications as branded filgrastim.

  • Drug Discovery And Development
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.

PLoS One; ##(##): e## Kotsopoulos J, et al. (2010).

  • Drug Discovery And Development
  • World
  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • Amgen Inc.

Consequent to the approval of Novartis' Filgrastim biosimilar in the US-the first biosimilar to receive FDA approval-it is expected that the focus on biosimilars will increase in the country.

  • Drug Discovery And Development
  • North America
  • United States
  • World
  • Horizon Discovery

Gland Surgery; ##(##): ##-## Zhang P, et al. (2016).

  • Drug Discovery And Development
  • World
  • Market Size
  • AstraZeneca PLC
  • Roche Group

Hypertension; ##(##): ## Johnston S, et al. (2016).

  • Drug Discovery And Development
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

The FDA requires that the biosimilar INN is followed by a four letter suffix, denoting the product manufacturer name, such as filgrastim-sndz in the case of the filgrastim TABLE ##: TRASTUZUMAB BIOSIMILARS, 2017 ##. ##. ## NOMENCLATURE biosimilar by Sandoz.

  • Drug Discovery And Development
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • Untitled
  • NIH Research Festival Exhibit

FDA approval of Novartis' s biosimilar filing for its filgrastim biosimilar.

  • Drug Discovery And Development
  • Charles River Laboratories International, Inc.
  • genOway SA
  • Horizon Discovery
  • Taconic Biosciences, Inc.
  • Clinical Trial profile. 89 Trial Title
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Maternal Health
  • World
  • Social Conditions

Clinical Hypertension; ##(##): ##.

  • Drug Discovery And Development
  • World
  • Market Size
  • Novartis AG
  • Sanofi S.A.

TERM=ABY-##& RANK=## ##. ##. ##.

  • Drug Discovery And Development
  • United States
  • Allergan plc
  • Molecular Partners AG
  • Roche Group

The company has provided a helpline number, ##-##-##ASSIST (##-##-##-##).

  • Drug Discovery And Development
  • North America
  • United States
  • Ablynx NV
  • Amgen Inc.

Clinical Medicine & Research; ##(##-##): ##-##.

  • Drug Discovery And Development
  • World
  • Market Size
  • Bristol-Myers Squibb Company
  • Novartis AG

Neupogen (filgrastim) ##.

  • Drug Discovery And Development
  • United States
  • AstraZeneca PLC
  • Pfizer Inc.
  • Roche Group

Neupogen (filgrastim) ##.

  • Drug Discovery And Development
  • North America
  • United States
  • ARIAD Pharmaceuticals, Inc.
  • Incyte Corporation

Neupogen (filgrastim) ##.

  • Drug Discovery And Development
  • North America
  • United States
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • CAR-T THERAPIES: DISTRIBUTION OF CLINICAL TRIALS BY TYPE OF THERAPY
  • 7.4.3. CLINICAL TRIAL ANALYSIS: DISTRIBUTION BY TYPE OF THERAPY

SR ONE ##.

  • Drug Discovery And Development
  • China
  • Celgene Corporation
  • Juno Therapeutics Inc.
  • Novartis AG

PLoS One; ##(##): epub ACR (2013).

  • Drug Discovery And Development
  • World
  • Market Size
  • Johnson & Johnson
  • Novartis AG
  • LA-EP 2006: CLINICAL TRIALS IN THE US, EU AND ROW

FILGRASTIM ##. ##. ##.

  • Drug Discovery And Development
  • North America
  • United States
  • Market Size
  • Sandoz Inc.

ua: ##.

  • Drug Discovery And Development
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SIZE, BY THERAPEUTIC AREA, 2013-2020 (USD MILLION)
  • 9.2 NORTH AMERICA

s Neupogen (filgrastim) which was licensed in 1991.

  • Drug Discovery And Development
  • North America
  • United States
  • Supply
  • Almac Discovery Ltd.
  • HODGKIN LYMPHOMA THERAPEUTICS CLINICAL TRIALS MARKET, GLOBAL, CLINICAL TRIALS BY AMGEN INC., 2015*

Hoffmann-La Roche Ltd. ## ## ## ## ## ## ## ## Amgen Inc. ## ## ## ## ## ## ## ## AbbVie Inc. ## ## ## ## ## ## ## ## Source: GlobalData' s Pharma eTrack Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2015 2015 trials are taken as of Augu

  • Drug Discovery And Development
  • World
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Seattle Genetics, Inc.
  • Primary Immune Deficiency (PID) Therapeutics, Global, Terminated Clinical Trials, 2015*

The prominent features of this report are - ##.

  • Drug Discovery And Development
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited

Neupogen (filgrastim) ##.

  • Drug Discovery And Development
  • United States
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Clinical Trial Product Information

Extrahepatic Bile Duct Cancer Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Extrahepatic Bile Duct Cancer Global Clinical Trials Review, H1, 2015" provides data on the Extrahepatic Bile Duct Cancer clinical trial scenario. This report provides elemental information and data relating...

  • Drug Discovery And Development
  • United States
  • World
  • AstraZeneca PLC
  • Daiichi Sankyo Company
  • SYNOVIAL SARCOMA THERAPEUTICS CLINICAL TRIALS MARKET, GLOBAL, CLINICAL TRIALS BY NATIONAL CANCER INSTITUTE, 2015*
  • CLINICAL TRIAL PRODUCT INFORMATION TRIAL TITLE

Subjects received TH-## at a dose of ##mg/ m intravenously over ##-## minutes on Days ## and ## and a full dose ##mg/ m by bolus injection two hours after TH-## starting on Day ## of a ##-day cycle, and G-CSF (filgrastim) on Day ##.

  • Drug Discovery And Development
  • Adaptimmune Therapeutics plc
  • Daiichi Sankyo Company
  • F. Hoffmann-La Roche Ltd.
  • Threshold

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Transplantation
  • World
  • Prograf group
  • PROMINENT DRUGS
  • Clinical Trial profile. 341 Trial Title

Neutropenia Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Neutropenia Global Clinical Trials Review, H1, 2018" provides an overview of Neutropenia clinical trials scenario.This report provides top line data relating to the clinical trials on Neutropenia. Report...

  • Blood Disease
  • Clinical Trial
  • Drug Discovery And Development
  • Therapy
  • World
  • Clinical Trial profile. 278 Trial Title
  • Clinical Trial profile. 236 Trial Title

Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017" provides an overview of Leukocyte Disorders (White Blood Cell Disorders)...

  • Blood Disease
  • Chemotherapy
  • Clinical Trial
  • Drug Discovery And Development
  • World
  • Clinical Trial profile. 50 Trial Title

Small Intestine Cancer Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Small Intestine Cancer Global Clinical Trials Review, H2, 2018" provides an overview of Small Intestine Cancer clinical trials scenario.This report provides top line data relating to the clinical...

  • Clinical Trial
  • Drug Discovery And Development
  • Oncology
  • World
  • Merck & Co., Inc.